/
KNSA
$77.83-$0.32 (-0.41%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$6.1B
78M shares
52-week range
$32.82 – $82.94
90% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$66.07
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
www.kiniksa.com- Employees
- 366
- IPO / List date
- May 24, 2018
- HQ
- LONDON
Held by traders on TradeandTell
No one on the platform currently holds KNSA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in KNSA as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded KNSA yet.
